On September 2, 2021 Alligator Bioscience AB ("Alligator" or the "Company") reported that the Company, in order to enable further progress, will begin evaluating potential financing alternatives, which may include issuance of equity (Press release, Alligator Bioscience, SEP 2, 2021, View Source [SID1234587144]). Alligator’s board has appointed financial advisors and the Company has received support from certain of the Company’s largest shareholders for continued funding of the Company.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

To give Alligator’s new and experienced management team the right opportunities to develop the Company, the Board’s current assessment is that working capital will need to be strengthened in order to enable phase II studies for Mitazalimab, phase II preparations for ATOR-1017 as well as the development of other pipeline candidates and general corporate purposes. The Company will now continue dialogues with relevant stakeholders, evaluate its available funding alternatives, and revert to the market with more information in due course.

This information is such information as Alligator Bioscience AB (publ) is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact persons set out above, at 12:00 p.m. CEST on September 2, 2021.